www.lipoxen.co.uk
Xenetic Biosciences (formally Lipoxen) is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs.
The company has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Xenetic Biosciences 's technologies include: PolyXen® - Protein drug delivery, ImuXen® - DNA, protein and polysaccharide vaccines and VesicALL® - Anti-cancer drugs using liposomal entrapment.
-
04/05/12
Xenetic Biosciences appoints special consultant to drive development of OncoHist candidate -
01/05/12
Xenetic Biosciences calls Dr Artur Isaev to the board as Igor Nikolaev resigns -
02/03/12
Xenetic Bioscience's share plan means good news for management is positive for shareholders - Singer -
13/02/12
Xenetic Biosciences doses its first intravenous patient with ErepoXen -
01/02/12
Xenetic Biosciences suspends open offer part of fundraising -
15/12/11
Xenetic Biosciences hit by news of further delay in completing German acquisition -
29/11/11
Xenetic Biosciences raises £12.2 million via share subscription -
07/11/11
Xenetic Biosciences, African Medical Investments and e-Therapeutics to appear at Proactive Investors -
26/10/11
Xenetic Biosciences begins process to close SynBio and SymbioTec deals -
30/09/11
Xenetic Biosciences to close German and Russian transactions by end of October -
03/06/11
Lipoxen says its technology platforms will prove their potential -
04/05/11
Lipoxen awarded US$100,000 grant to develop polio vaccine -
16/12/10
Lipoxen reports encouraging phase II results for ErepoXen -
29/11/10
Lipoxen’s Russian drug development partner lands £10.7 mln IPO on MICEX -
19/10/10
Lipoxen to accelerate ImuXen flu vaccine to Phase 1 trial -
20/09/10
Lipoxen drug pipeline progressing nicely -
21/06/10
Lipoxen extends PolyXen patent family in the US -
14/06/10
Lipoxen and Baxter confident that PolyXen-based haemophilia treatments will move into clinical devel -
26/05/10
Lipoxen expands its US DNA Vaccine Patent for ImuXen -
26/05/10
Lipoxen expands its US DNA Vaccine Patent for ImuXen -
28/04/10
Lipoxen receives positive results for ImuXen candidates for influenza and malaria -
26/04/10
Lipoxen CEO, CFO buy 250,000 further shares in company -
01/03/10
Lipoxen and Serum Institute of India start Phase II trial for ErepoXen -
01/03/10
Lipoxen and Serum Institute of India start Phase II trial for anaemia treatment ErepoXen -
08/02/10
Lipoxen granted EU patent for polysialic acid technology StimuXen -
05/02/10
Lipoxen H2 revenue hit by EPO and Insulin delays, foresees positive news flow in 2010 -
14/01/10
Lipoxen's PolyXen bio-polymer technology wins US Patent -
16/11/09
Lipoxen in research collaboration with Russia’s Pharmsynthez -
30/09/09
Lipoxen narrows H1 losses, named lead company in UK vaccine research programme -
29/06/09
Lipoxen wins DNA vaccine patent in EU and US for ImuXen
Sorry, no media files found.
